NCT00346684

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: University of Cologne · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab

Conditions

• Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)

Interventions

Type	Name	Description
DRUG	Rituximab

Timeline

• Start date: 2006-07-01
• Primary completion: 2007-11-01
• First posted: 2006-06-30
• Last updated: 2008-08-12

Locations

1 site across 1 country: Germany